Table 2. Effect of PMX : CPT-11 combination on cell recovery, cell cycle, caspase 3/7 activation and clonogenicity: 5 days after 48 h exposure.

			Cell recovery			Cell cycle (%)
Cell linea	Sourceb	PMX–CPT-11	Cell number (× 106)	%	%Caspase 3/7+	SubG1	G1	S	G2	Hyper G2	G2/G1	Clonogenicity (clone number)
MIAPaCa2	P	−	0.56		1	27	51	6	11	6	0.22	5.25
		+	0.52	94	4.5	37	57	3	3	0	0.05	2
PaCa3	P	−	0.68		7.1	9	54	10	23	5	0.43	9.3
		+	0.76	111	16.9	20	31	11	27	11	0.88	7.9
SK-PC 1	P	−	0.22		0.8	15	57	9	12	8	0.21	2.5
		+	0.1	44	2.5	54	12	23	6	6	0.54	1.25
PANC-2	P	−	1.02		32	7	44	17	22	12	0.50	13
		+	0.08	8	57.7	55	8	12	10	14	1.18	2.5
CFPAC1	M	−	0.30		34.7	20	36	7	21	17	0.60	2.75
		+	0.19	56	31.8	47	10	11	19	13	1.96	1.31
PC	M	−	0.20		0.8	4	54	5	22	15	0.41	7.5
		+	0.10	50	7.4	15	13	25	24	25	1.85	3.5
HS766T	M	−	0.25		1.8	7	46	8	19	20	0.41	4.75
		+	0.15	60	7.6	16	19	23	18	25	0.95	1.25
Capan-1	M	−	0.12		3.7	59	21	5	8	7	0.36	4.25
		+	0.07	57	17.6	88	7	2	1	1	0.19	1.75
T3M4	M	−	0.45		15	16	40	2	17	24	0.43	3.75
		+	0.05	12	31	84	11	1	2	1	0.18	1
A818-4	A	−	0.24		8	6	47	13	23	10	0.49	4.25
		+	0.14	58	15	13	20	30	29	9	1.45	1.75
Median		−	0.28		5.4	11.6	46.7	7.7	20.2	10.8	0.41	4.5
		+	0.1		15.9	41.9	12.3	11.8	14.2	9.8	0.91	1.75
P c			0.009		0.005	0.005	0.007	NS	NS	NS	0.028	0.005

^aData reported are the mean of two experiments for each cell line.

^bP=primary tumour; M=liver or lymph nodes metastasis; A=ascites.

^cWilcoxon Signed Rank test; NS=not statistically different.

PMX=pemetrexed; CPT-11=irinotecan.